Brief CV

NAME: Massimo Federici

DATE OF BIRTH:

POSITION TITLE: Professor of Medicine, Director of the Center for Atherosclerosis, University of Rome "Tor

Vergata"

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
MEDICAL DOCTOR - University of Rome	MD	1994	Medicine
Board of Internal Medicine - University of Rome	MD	1995	Medicine
Research Fellow- Harvard Medical School – Joslin Diabetes Center	MD	1996-1997	Metabolism
Board of Endocrinology		1995-1999	

A. Positions and Honours

1999-2002 University of Rome Tor Vergata, Italy: Assistant Professor of Internal Medicine and Clinical Registar at the Dept. of Medicine at Tor Vergata University Hospital.

2002-2008 University of Rome Tor Vergata, Italy: Associate Professor of Internal Medicine, Atherosclerosis and Metabolism

2005 Morgagni Silver Prize

2006 EASD Rising Star Lecture

2007-present Managing Editor, ActaDiabetologica

2008-2017 Associate Editor, Atherosclerosis

2010 Alcmeone SID Prize

2010-2015 Adjunct Professor of Medicine, Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio

2006-present University of Rome Tor Vergata, School of Medicine: Professor of Medicine and Nutrition **2008-present** University of Rome Tor Vergata Hospital "Policlinico Tor Vergata", Director of the Center for Atherosclerosis

B. Publications

H-index (Scopus author ID 7006237353)	44
Total Citations (Scopus)	6285
Original Articles, reviews, letters	158

C. Research Support (over the last 10 years)

1.Ongoing Research Support:2014-2017 Coordinator (National Project) PRIN 2012 "GENI, AMBIENTE E METABOLISMO: PREDITTORI, MODULATORI E MARCATORI DELL'INVECCHIAMENTO VASCOLARE E DEL RISCHIO CARDIOMETABOLICO"; 2015-2017PI, Fondazione Roma NCD call 2014 project "Advantages and Pitfalls in using the metabolic polarization concept as therapeutics for the Metabolic Syndrome and its complications"; 2015-2017 Co-Principal Investigator, RFS2011-2012 ISS "THE ROLE OF THE BRAIN-ADIPOCYTE AXIS ACTIVITY IN POTENTIATING ANTIDEPRESSANT EFFICACY" 2.Completed Research Support:2010-2014Co-PI (Italy), FP7-HEALTH-2009 GA241913 "The role of intestinal microflora in non-alcoholic fatty liver disease (NAFLD) (FLORINASH)"; 2011-2015Co-PI (Italy), FP7-HEALTH-2010 "Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population"; 2013-2015PIFo-Ri.SID. project "Translational application of FoxO1 deacetylation in the setting of diabetic cardiomyopathy"; 2014-2016 PI AIRC project "Exploring TIMP3 as potential therapeutic agent in obesity-related hepatocellular carcinoma"; 2014-2016 EFSD/Lilly European Diabetes Research Programme "TIMP3 modulates immune cell microenvironment in a model of metabolic disease":